• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

    2.750 -0.210 (-7.09%)
    Streaming Delayed Price Updated: 10:05 AM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 231,832
    Open 2.930
    Bid (Size) 2.740 (200)
    Ask (Size) 2.760 (200)
    Prev. Close 2.960
    Today's Range 2.740 - 2.990
    52wk Range 0.9100 - 4.200
    Shares Outstanding 28,804,411
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
    From Entera Bio Ltd.
    Via GlobeNewswire

    Performance

    YTD
    +55.4%
    +55.4%
    1 Month
    +60.8%
    +60.8%
    3 Month
    +147.7%
    +147.7%
    6 Month
    +106.8%
    +106.8%
    1 Year
    +32.2%
    +32.2%

    More News

    Read More
    Which stocks are moving on Monday? ↗
    Via Chartmill
    Curious about the most active stocks on Monday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
    From Entera Bio Ltd.
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
    From Entera Bio Ltd.
    Via GlobeNewswire
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead ↗
    Via Stocktwits
    Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
    Via AB Newswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    Could Oral Osteoporosis Treatment Become the Next GLP-1-Style Blockbuster?
    Via AB Newswire
    News headline image
    Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
    Via AB Newswire
    News headline image
    Entera Bio Beats Q2 EPS Estimates ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024 ↗
    Via InvestorPlace

    Frequently Asked Questions

    Is Entera Bio Ltd. - Ordinary Shares publicly traded?
    Yes, Entera Bio Ltd. - Ordinary Shares is publicly traded.
    What exchange does Entera Bio Ltd. - Ordinary Shares trade on?
    Entera Bio Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Entera Bio Ltd. - Ordinary Shares?
    The ticker symbol for Entera Bio Ltd. - Ordinary Shares is ENTX on the Nasdaq Stock Market
    What is the current price of Entera Bio Ltd. - Ordinary Shares?
    The current price of Entera Bio Ltd. - Ordinary Shares is 2.750
    When was Entera Bio Ltd. - Ordinary Shares last traded?
    The last trade of Entera Bio Ltd. - Ordinary Shares was at 08/04/26 10:05 AM ET
    What is the market capitalization of Entera Bio Ltd. - Ordinary Shares?
    The market capitalization of Entera Bio Ltd. - Ordinary Shares is 79.21M
    How many shares of Entera Bio Ltd. - Ordinary Shares are outstanding?
    Entera Bio Ltd. - Ordinary Shares has 79M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.